Issue 10/2019
Content (11 Articles)
Predictive Value of Microdose Pharmacokinetics
Merel van Nuland, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
Elise J. Smolders, Anouk M. E. Jansen, Peter G. J. ter Horst, Jürgen Rockstroh, David J. Back, David M. Burger
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Wonkyung Byon, Samira Garonzik, Rebecca A. Boyd, Charles E. Frost
Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016
Anitha Saravanakumar, Armin Sadighi, Rachel Ryu, Fatemeh Akhlaghi
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease
Carl Amilon, Mohammad Niazi, Anders Berggren, Magnus Åstrand, Bengt Hamrén
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials
Ahmed A. Suleiman, Mukul Minocha, Amit Khatri, Yinuo Pang, Ahmed A. Othman
Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis
Ryan L. Crass, Manjunath P. Pai
A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients
Cornelis Smit, Roeland E. Wasmann, Sebastiaan C. Goulooze, Eric J. Hazebroek, Eric P. A. Van Dongen, Desiree M. T. Burgers, Johan W. Mouton, Roger J. M. Brüggemann, Catherijne A. J. Knibbe
Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis
Dario Cattaneo, Sara Baldelli, Andrea Giacomelli, Davide Minisci, Paola Meraviglia, Noemi Astuti, Marta Fusi, Valeria Cozzi, Emilio Clementi, Massimo Galli, Cristina Gervasoni
Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
Philippe Lechat, Jacques Ropers, Jérome Barré, Stephane Mouly
Authors’ Reply to Lechat et al.: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, Pierre-Louis Toutain